Opinion
Video
Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC
Author(s):
Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.
When treating with androgen receptor-targeted therapies, what are some of the considerations to make towards the sequencing of these agents and weighing their benefits in first line versus second line?
Related Videos
Related Content
